688298 東方生物
按盤價 
24.130 -0.140 (-0.577%) | 2025/09 - 九個月 人民幣(K¥) | 與去年同期 比較 | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | ||
| 營業總收入 | 671,812 | 2.16% | 827,916 | 820,157 | 8,767,938 | 10,169,168 | |
| 減：營業總成本 | 898,682 | -11.53% | 1,250,501 | 1,002,299 | 5,068,043 | 4,367,203 | |
| 其中:營業成本 | 392,089 | -8.71% | 565,130 | 467,403 | 4,314,399 | 2,665,325 | |
| 財務費用 | (72,637) | 58.18% | (217,336) | (275,581) | (603,272) | 67,239 | |
| 資產減值損失 | (16,473) | -1.01% | (175,703) | (236,509) | (1,209,740) | (16,671) | |
| 公允價值變動收益 | 4,988 | -67.10% | 10,655 | (8,990) | 1,660 | 44 | |
| 投資收益 | 5,520 | -92.20% | 29,777 | 42,014 | 6,023 | 11,148 | |
| 其中：對聯營企業和合營企業的投資收益 | (2,079) | -13.12% | (3,019) | (1,498) | 1,914 | -- | |
| 營業利潤 | (234,217) | -17.11% | (578,831) | (383,835) | 2,528,210 | 5,776,399 | |
| 利潤總額 | (234,723) | -15.47% | (585,311) | (404,227) | 2,470,752 | 5,769,966 | |
| 減：所得稅費用 | (3,549) | 2.58% | (16,488) | 14,042 | 373,321 | 829,320 | |
| 淨利潤 | (231,174) | -15.70% | (568,822) | (418,269) | 2,097,431 | 4,940,646 | |
| 減：非控股權益 | (18,542) | 53.60% | (39,800) | (20,685) | 29,717 | 20,458 | |
| 股東淨利潤 | (212,632) | -18.89% | (529,023) | (397,584) | 2,067,714 | 4,920,188 | |
市場價值指標 | |||||||
| 每股收益 (元) * | -1.100 | -16.67% | -2.690 | -1.970 | 12.310 | 41.000 | |
| 每股派息 (元) * | -- | -- | -- | -- | 2.000 | 6.180 | |
| 每股淨資產 (元) * | 31.551 | -7.55% | 32.962 | 36.885 | 48.588 | 57.143 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 26/12/2025 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
